Angiogenesis Inhibitors, Cancer-Associated Thrombosis, and Bleeding

2007 ◽  
pp. 93-112
BIO-PROTOCOL ◽  
2016 ◽  
Vol 6 (19) ◽  
Author(s):  
Laura Winters ◽  
Nithya Thambi ◽  
Julian Andreev ◽  
Frank Kuhnert

2021 ◽  
Vol 200 ◽  
pp. S72-S73
Author(s):  
R. Patell ◽  
T. Chiasakul ◽  
R. Redd ◽  
A.M. Khan ◽  
E.P. McCarthy ◽  
...  

2021 ◽  
Vol 28 (1) ◽  
pp. 661-670
Author(s):  
Lawrence Kasherman ◽  
Jeffrey Doi ◽  
Katherine Karakasis ◽  
Jeffrey Schiff ◽  
Abhijat Kitchlu ◽  
...  

Solid organ transplant recipients on long-term immunosuppressive medication are at increased risk of developing malignancy, and treatment of advanced cancers with angiogenesis inhibitors in this context has not been widely studied. We present a case of recurrent high-grade serous ovarian carcinoma treated with paclitaxel and bevacizumab in the context of prior renal transplantation where the patient responded well to treatment with controlled toxicities, discussing the potential for increased rates of adverse events and drug interactions in this select population.


2021 ◽  
Vol 22 (5) ◽  
pp. 2627
Author(s):  
Francisco Galeano-Valle ◽  
Lucía Ordieres-Ortega ◽  
Crhistian Mario Oblitas ◽  
Jorge del-Toro-Cervera ◽  
Luis Alvarez-Sala-Walther ◽  
...  

The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients.


Author(s):  
Behnood Bikdeli ◽  
David Jiménez

No Abstract


Sign in / Sign up

Export Citation Format

Share Document